Evolutionary Hypothesis in Cell Cycle of Breast Cancer Patients: Mosaic Phases in Single Cancer Cells
Keywords:Cell cycle, Mosaic Phases, evolutionary hypothesis, breast cancer, FISH, Protein expression
Introduction: Cell cycle shapes the initiation, progression and therapeutic approaches of neoplasms. An uncontrolled cell proliferation and growth are the key characteristics of either malignant or benign tumors. The programmed check points control the transition of phases through the related barriers. Therefore, balancing the carcinogenic processes may inhibit progression and facilitate a targeted-base therapy.
Methods: The present study is performed in interphase. Detection of the Mosaic Phases (MPs) by Fluorescence In Situ Hybridization was confirmed by assaying the protein expression (PE) including immunofluorescence and flow cytometry.
Results: The novel hypothesis reflects the presence of dual and/or multi-phases, as minor clones in single cells of breast cancer (BC) patients. This finding led to initiate a model with applicable ratio values and different MPs including G1/S, S/G2 and G1/S/G2, accompanied by normal phases (G1, S, G2). The remarkable harmonic behaviors between signal copy numbers and the corresponding PE, dual- and triple- co-expression between different cyclins combination including E/B1 and D1/E/B1 and the other involved proteins were observed. The ratio of gain to normal signals appeared to be a good prognosis for chromosome 1, but better survival was significantly obtained for this ratio in chromosome 3
Conclusion: The predisposing-diagnostic-predictive-prognostic-preventive panels may lead to innovate the CDKs inhibitor-based therapy by considering the MPs Model; and may also be considered for clinical classification, in BC and other cancers.
Belanger H, Beaulieu P, Moreau C, Labuda D, Hudson TJ, Sinnett D. Functional Promoter SNPs in Cell Cycle Checkpoint Genes. Human Molecular Genetics 2005; 4: 2641-8. https://doi.org/10.1093/hmg/ddi298 DOI: https://doi.org/10.1093/hmg/ddi298
Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clinical Cancer Research 2014; 20: 3379-3383. https://doi.org/10.1158/1078-0432.CCR-13-1551 DOI: https://doi.org/10.1158/1078-0432.CCR-13-1551
Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D. Genome-wide association study identifies five new BC susceptibility loci. Nature Genetics 2010; 42: 504-507. https://doi.org/10.1038/ng.586 DOI: https://doi.org/10.1038/ng.586
Siegel PM, Hardy WR, Muller WJ. Mammary gland neoplasia: insights from transgenic mouse models. Bioessays 2000; 22: 554-563. https://doi.org/10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A DOI: https://doi.org/10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A
Salmon ES, Sartorelli AC. Cancer Chemotherapy. In: Katzung. BG, editor. Basic & Clinical Phamacology, Appleton & Lange. UK: 1998; 881-915.
Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448: 811-815. https://doi.org/10.1038/nature06046 DOI: https://doi.org/10.1038/nature06046
Schwanitz G, Raff R. Application of specific cytologic, cytogenetic and molecular-cytogenetic techniques for the characterization of solid tumors. Annales Academiae Medicae Bialostocensis 2005; 50: 91-96.
Therman Eva. Human chromosomes, structure, behavior, effects.2nd ed. Heidelberg: Springer-Verlag, 1986; 273-281. https://doi.org/10.1007/978-1-4684-0269-8_27 DOI: https://doi.org/10.1007/978-1-4684-0269-8_27
White MJD. Mitotic cycle. In: Human chromosomes, structure, behavior, effects. 2nd ed. Heidelberg: Springer-Verlag,Therman E, editor, 1986; 28-29.
Mehdipour P, Pirouzpanaha S, Sarafnejad A, Atri M Shahrestani T, Haidari M. Prognostic implication of CDC25A and cyclin E expression on primary BC patients. Cell Biology International 2009; 33: 1050-1056. https://doi.org/10.1016/j.cellbi.2009.06.016 DOI: https://doi.org/10.1016/j.cellbi.2009.06.016
Sandberg AA. The chromosomes in human cancer and leukemia. 1st ed. New York: Elsevier 1980; 75.
Miklos GLG, John B. Heterochromatin and satellite DNA in man: properties and prospects. Am J Hum Genet 1979; 31: 264-280.
Wilson EB. The cell in development and heredity. 3rd editor. New York: McMillian, 1925.
Kyte J, Doolittle RFA. simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157: 105-32. https://doi.org/10.1016/0022-2836(82)90515-0 DOI: https://doi.org/10.1016/0022-2836(82)90515-0
Flavell RB. Sequence amplification, deletion and rearrangement:Major source of variation during species of divergence, 1982. In: Therman E, editor. Human chromosomes, structure, behavior, effects.2nd edn. Heidelberg: Springer-Verlag, 1986; 52-57.
Miklos GLG, Amanda Clare Gill AC. Sequencing and of high repeated DNA. Compilation and Comments 1982; 39: 1-30. https://doi.org/10.1017/S0016672300020711 DOI: https://doi.org/10.1017/S0016672300020711
Therman E, Kuhn EM. Mitotic modifications and aberrations in cancer. CRC. Crit Rev Oncogen 1989; 1: 293-305.
Lodisch H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J, Eds. Molecular cell Biology. New York: Media Connected, 2000; 524-526.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.